Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Rhea-AI Summary

Eloxx Pharmaceuticals (Nasdaq: ELOX) reported second quarter 2026 results and a major strengthening of its capital position following a completed underwritten public offering with $66.0 million in gross proceeds and uplisting to the Nasdaq Capital Market. Net proceeds were approximately $58.3 million, contributing to $62.0 million in cash and cash equivalents as of June 30, 2026, which the company expects will fund operations into mid‑2028 and through data readouts for exaluren in Alport syndrome and ADPKD.

Eloxx obtained FDA clearance to proceed with a Phase 2b trial of exaluren in nonsense mutation Alport syndrome, targeted to start in the third quarter of 2026, with topline 16‑week data expected by mid‑2027. Exaluren has orphan drug designation for Alport syndrome in the US and EU, and in July 2026 the European Commission granted orphan designation for exaluren in ADPKD. A Phase 2 ADPKD trial is planned for 2027. Second quarter 2026 net loss was $4.5 million, compared with $1.9 million a year earlier, driven by higher R&D and G&A expenses as clinical and corporate activities expanded.

Positive

• $66.0 million gross proceeds from June 2026 underwritten public offering
• Net proceeds of $58.3 million boosted cash to $62.0 million at June 30, 2026
• Cash runway expected to fund operations into mid‑2028
• Uplisting to Nasdaq Capital Market completed in June 2026
• FDA cleared Phase 2b exaluren trial in nonsense mutation Alport syndrome
• EU orphan designation granted for exaluren in ADPKD in July 2026
• Eligibility for up to $470.0 million ZKN‑013 milestones plus tiered royalties

Negative

• Quarterly net loss rose to $4.5 million from $1.9 million year over year
• Six‑month 2026 net loss increased to $8.3 million from $3.6 million in 2025
• R&D expenses grew to $2.8 million from $0.9 million in the quarter
• G&A expenses rose to $1.6 million from $0.7 million year over year
• Equity offering of 2,975,000 shares plus 3,025,000 pre‑funded warrants implies shareholder dilution

News Explained

New shares already reduce existing ownership, while the warrants can reduce it further if exercised.

Eloxx completed its June 2026 underwritten public offering, receiving approximately $58.3 million net from $66.0 million gross; it issued 2,975,000 common shares and pre-funded warrants for up to 3,025,000 additional shares, creating potential dilution for existing common holders if the warrants become shares.

An underwritten offering means an investment bank buys securities from the issuer for resale, and underwriting fees help explain why net proceeds were below gross proceeds.

The pre-funded warrants are sold near full share price with nominal exercise price and convert to shares when exercised; issuing those shares increases total share count and reduces existing holders' percentage ownership absent offsetting changes.

The company also effected a one-for-eleven reverse stock split in May 2026 and reduced authorized common shares from 500,000,000 to 100,000,000; the split consolidates shares and raises the per-share price proportionally, without changing company value by itself.

Market Context

A prior offering announcement had a 170.52% 24-hour price reaction, giving the platform a concrete c...

Analysis

A prior offering announcement had a 170.52% 24-hour price reaction, giving the platform a concrete comparison for this financing and quarterly update. The release paired stronger liquidity with higher expenses; continuing losses remained a key risk.

Key Figures

Gross proceeds: $66.0 million Net proceeds: $58.3 million Cash and equivalents: $62.0 million +4 more

7 metrics

Gross proceeds $66.0 million June 2026 public offering

Net proceeds $58.3 million After underwriting discounts, commissions, and offering expenses

Cash and equivalents $62.0 million As of June 30, 2026

Net loss $4.5 million Three months ended June 30, 2026

R&D expenses $2.8 million Three months ended June 30, 2026

Phase 2b trial initiation Third quarter of 2026 Exaluren in nonsense mutation Alport syndrome

Development and sales milestones Up to $470.0 million ZKN-013 license with Almirall

Historical Context

1 past event · Latest: Jun 08 (Positive)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 08	Public offering	Positive	+170.5%	Offering pricing and Nasdaq uplisting preceded a 170.52% 24-hour gain.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The sole recent historical event was a public offering followed by a 170.52% 24-hour gain, providing limited evidence of a broader reaction pattern.

Key Terms

underwritten public offering, pre-funded warrants, investigational new drug application, orphan drug designation, +1 more

5 terms

underwritten public offering financial

"Completed an underwritten public offering with gross proceeds of $66.0 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"together with pre-funded warrants to purchase up to 3,025,000 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

investigational new drug application regulatory

"clearance under its Investigational New Drug application from the U.S. Food and Drug"

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

orphan drug designation regulatory

"Exaluren has received orphan drug designation from the FDA and European Commission"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

reverse stock split financial

"the Company effected a one-for-eleven reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet
• Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026
• European Commission granted orphan designation for exaluren in ADPKD
• Cash and cash equivalents of $62.0 million as of June 30, 2026, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD)

ARLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.

"The second quarter was transformational for Eloxx. Our public offering, with gross proceeds of $66.0 million, together with our uplisting to the Nasdaq Capital Market, has meaningfully strengthened our balance sheet and provides the resources to advance exaluren across our rare kidney disease programs," said Sumit Aggarwal, President and Chief Executive Officer of Eloxx. "With approximately $62.0 million in cash, no outstanding debt, and a clear clinical development plan, we believe we are well positioned to advance our Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome in the third quarter of 2026 and initiate a Phase 2 clinical trial in nonsense mutation ADPKD in 2027."

Financing and Uplisting to Nasdaq

• $66.0 million public offering. The Company completed an underwritten public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share, together with pre-funded warrants to purchase up to 3,025,000 shares of common stock, for gross proceeds of approximately $66.0 million and net proceeds of approximately $58.3 million, after deducting underwriting discounts and commissions and offering expenses.
• Uplisting to Nasdaq. In June 2026, the Company completed its uplisting to the Nasdaq Capital Market, where its common stock began trading under the symbol "ELOX."

Recent Business Highlights

• Exaluren in nonsense mutation Alport syndrome (NMAS). The Company received clearance under its Investigational New Drug application from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 2b clinical trial of exaluren in patients with NMAS and plans to initiate the trial in the third quarter of 2026. The Company anticipates topline data from the initial 16-week placebo-controlled portion of the study by mid-2027, with the final readout by the end of 2027. Exaluren has received orphan drug designation from the FDA and European Commission for the treatment of Alport syndrome.
• Exaluren in ADPKD. In July 2026, the European Commission granted orphan medicinal product designation in the European Union for exaluren for the treatment of ADPKD. The Company plans to initiate a Phase 2 clinical trial of exaluren in nonsense mutation ADPKD in 2027, with topline data anticipated by mid-2028.
• Strengthened Board of Directors. In May 2026, the Company appointed Stephen W. Webster and Nina Kjellson to its board of directors. Mr. Webster served as Chief Financial Officer of Spark Therapeutics, Inc. from 2014 until its acquisition by Roche in 2019, has previously held chief financial officer roles at Optimer Pharmaceuticals and Adolor Corporation, and currently serves as a director of Cullinan Therapeutics, Inc. and NextCure, Inc. Ms. Kjellson has been a General Partner at Canaan Partners since 2015 and previously served as a General Partner at InterWest Partners, bringing more than two decades of biotechnology investment and board experience.
• ZKN-013. Almirall, S.A., is developing ZKN-013 for the treatment of rare dermatological diseases associated with nonsense mutations, including recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. The Company remains eligible to receive development and sales milestones of up to approximately $470.0 million, as well as tiered royalties on any future global sales.

Second Quarter 2026 Financial Results

In May 2026, the Company effected a one-for-eleven reverse stock split of its common stock and reduced its authorized shares of common stock from 500,000,000 to 100,000,000. All share and per-share amounts in this press release reflect the reverse stock split.

Net loss for the three months ended June 30, 2026 was $4.5 million, or $(0.39) per share, which included $0.1 million in stock-based compensation, compared to a net loss of $1.9 million, or $(5.45) per share, for the same period in 2025. For the six months ended June 30, 2026, net loss was $8.3 million, compared to $3.6 million for the same period in 2025.

Research and development (R&D) expenses were $2.8 million for the three months ended June 30, 2026, compared to $0.9 million for the same period in 2025. The increase was primarily related to increased clinical trial expenses in support of the Company's exaluren program, as well as increases in personnel costs and preclinical research and development activities.

General and administrative (G&A) expenses were $1.6 million for the three months ended June 30, 2026, compared to $0.7 million for the same period in 2025. The increase was primarily related to higher professional and consulting fees, including legal, audit and tax fees, and increased personnel costs.

Cash position. As of June 30, 2026, the Company had cash and cash equivalents of $62.0 million, which includes approximately $58.3 million in net proceeds from the June 2026 public offering. The Company believes its cash and cash equivalents will be sufficient to fund its operations into mid-2028.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx's lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.

For more information, please visit www.eloxxpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation statements regarding the sufficiency of the Company's cash and cash equivalents to fund its operations; the expected timing of the initiation of, and results from, clinical trials of the Company's product candidates, including the Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome and a planned Phase 2 clinical trial in ADPKD; the potential benefits of orphan drug designation; the Company's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market; the Company's collaboration with Almirall and the potential to receive milestone and royalty payments; and the potential of the Company's product candidates to treat nonsense mutations, are forward-looking statements. Forward-looking statements can be identified by words such as "aim," "may," "will," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "potential," "seeks," or "continue," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and are subject to known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied due to various important factors, including, but not limited to, the Company's need for and ability to obtain additional capital; the uncertainty and expense of clinical development; the fact that results from preclinical studies and early clinical trials are not necessarily predictive of future results; and other important factors discussed under the caption "Risk Factors" and elsewhere in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 and its other filings with the SEC, accessible on the SEC's website at www.sec.gov and on the "Financials & Filings" page of the Company's website. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements contained herein.

Contact

Investor Relations
Eloxx Pharmaceuticals, Inc.
ir@eloxxpharma.com 
(781) 577-5300

ELOXX PHARMACEUTICALS, INC. Condensed Consolidated Statements of Operations  (in thousands, except share and per share amounts) (unaudited)
		Three Months Ended  June 30,				Six Months Ended  June 30,
		2026		2025		2026		2025
Operating expenses:
Research and development		$                 2,840		$                    898		$                 4,500		$                 1,408
General and administrative		1,610		684		3,746		1,396
Total operating expenses		4,450		1,582		8,246		2,804
Loss from operations		(4,450)		(1,582)		(8,246)		(2,804)
Other expense, net		52		309		10		796
Net loss		$               (4,502)		$               (1,891)		$               (8,256)		$               (3,600)
Net loss per share, basic and diluted		$                 (0.66)		$                 (5.45)		$                 (1.48)		$               (10.39)
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic and diluted		6,789,165		347,000		5,592,596		346,482

 

ELOXX PHARMACEUTICALS, INC. Consolidated Balance Sheet Data (in thousands, except share and per share amounts)
		June 30, 2026		December 31, 2025
		(unaudited)
Cash and cash equivalents		$               61,960		$                 4,785
Total assets		63,388		5,270
Total current liabilities		16,968		17,177
Total stockholders' equity (deficit)		46,420		(11,907)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/eloxx-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business-update-302849070.html

SOURCE Eloxx Pharmaceuticals, Inc.

FAQ

What were Eloxx Pharmaceuticals (ELOX) key financial results for Q2 2026?

Eloxx reported a Q2 2026 net loss of about $4.5 million, compared with $1.9 million a year earlier. According to Eloxx, R&D expenses rose to $2.8 million and G&A expenses to $1.6 million as clinical and corporate activities expanded.

How much cash does Eloxx Pharmaceuticals (ELOX) have after its June 2026 offering?

Eloxx reported $62.0 million in cash and cash equivalents as of June 30, 2026, including approximately $58.3 million in net offering proceeds. According to Eloxx, this cash is expected to fund operations into mid‑2028 and through key exaluren data readouts.

What were the terms of Eloxx Pharmaceuticals (ELOX) June 2026 stock offering?

Eloxx completed an underwritten public offering of 2,975,000 common shares at $11.00 per share and pre‑funded warrants for 3,025,000 shares. According to Eloxx, the transaction generated about $66.0 million gross and $58.3 million net proceeds.

What is the status of Eloxx Pharmaceuticals’ exaluren trial for nonsense mutation Alport syndrome?

The FDA cleared Eloxx to proceed with a Phase 2b trial of exaluren in nonsense mutation Alport syndrome, expected to start in Q3 2026. According to Eloxx, topline data from the 16‑week placebo‑controlled portion are anticipated by mid‑2027, with final readout by end‑2027.

Did Eloxx Pharmaceuticals (ELOX) receive orphan drug designation for exaluren in ADPKD?

Yes. In July 2026, the European Commission granted orphan medicinal product designation for exaluren in ADPKD. According to Eloxx, a Phase 2 trial in nonsense mutation ADPKD is planned for 2027, with topline data expected by mid‑2028.

How long is Eloxx Pharmaceuticals’ (ELOX) cash runway based on Q2 2026 figures?

Based on its June 30, 2026 cash balance of $62.0 million, Eloxx expects funding to last into mid‑2028. According to Eloxx, this runway should support operations through data readouts for both Alport syndrome and ADPKD exaluren programs.

What potential milestone payments could Eloxx Pharmaceuticals receive from the ZKN-013 partnership?

Eloxx remains eligible for up to approximately $470.0 million in development and sales milestones from Almirall for ZKN‑013. According to Eloxx, the company also expects tiered royalties on any future global sales of ZKN‑013 for rare dermatological diseases.